Apyx Medical Corp (APYX) Spending and interest coverage
- R&D / revenue · 12 months: Value 5.65%; Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 4.14%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 5.65% | Research and development expense / revenue. Period ending 2026-06-30. $3.30M ÷ $58.41M × 100 ≈ 5.65% |
| Stock-based compensation / revenue · 12 months | 4.14% | Share-based compensation / revenue. Period ending 2026-06-30. $2.42M ÷ $58.41M × 100 ≈ 4.14% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 3.30M USD | Research and Development Expense |
| Revenue | 58.41M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 2.42M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -3.54M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $3.30M | $58.41M | $2.42M | $-3.54M | (m) | 5.65% | 4.14% | (m) | (m) |
| 2026-03-31 | $3.33M | $55.90M | $1.86M | $-4.31M | (m) | 5.96% | 3.33% | (m) | (m) |
| 2025-12-31 | $3.37M | $52.84M | $2.00M | $-6.45M | (m) | 6.38% | 3.79% | (m) | (m) |
| 2025-09-30 | $3.55M | $47.90M | $2.34M | $-9.51M | (m) | 7.40% | 4.88% | (m) | (m) |
| 2025-06-30 | $3.89M | $46.51M | $2.81M | $-12.31M | (m) | 8.36% | 6.03% | (m) | (m) |
| 2025-03-31 | $4.49M | $47.29M | $3.34M | $-15.28M | (m) | 9.49% | 7.05% | (m) | (m) |
| 2024-12-31 | $5.08M | $48.10M | $4.01M | $-18.84M | (m) | 10.56% | 8.34% | (m) | (m) |
| 2024-09-30 | $4.77M | $48.54M | $4.09M | $-21.57M | (m) | 9.83% | 8.42% | (m) | (m) |
| 2024-06-30 | $5.04M | $49.03M | $4.44M | $-22.57M | $4.52M | 10.27% | 9.06% | -4.99× | Reported |
| 2024-03-31 | $4.97M | $50.45M | $4.88M | $-18.26M | $3.64M | 9.85% | 9.66% | -5.02× | Reported |
| 2023-12-31 | $4.84M | $52.35M | $5.11M | $-17.26M | $2.48M | 9.25% | 9.77% | -6.96× | Reported |
| 2023-09-30 | $4.85M | $50.30M | $5.84M | $-17.45M | $1.36M | 9.64% | 11.61% | -12.79× | Reported |
| 2023-06-30 | $4.64M | $47.44M | $6.18M | $-18.60M | $781.00K | 9.77% | 13.03% | -23.81× | Reported |
| 2023-03-31 | $4.51M | $44.16M | $6.41M | $-23.34M | $241.00K | 10.21% | 14.52% | -96.85× | Reported |
| 2022-12-31 | $4.54M | $44.51M | $6.70M | $-23.56M | $15.00K | 10.21% | 15.05% | -1570.80× | Reported |
| 2022-09-30 | $4.24M | $48.72M | $6.40M | $-19.32M | $13.00K | 8.69% | 13.13% | -1486.23× | Reported |
| 2022-06-30 | $4.35M | $51.44M | $5.89M | $-17.51M | $15.00K | 8.46% | 11.45% | -1167.13× | Reported |
| 2022-03-31 | $4.36M | $52.37M | $5.54M | $-15.57M | $14.00K | 8.33% | 10.59% | -1112.43× | Reported |
| 2021-12-31 | $4.32M | $48.52M | $5.09M | $-14.45M | $10.00K | 8.91% | 10.49% | -1444.80× | Reported |
| 2021-09-30 | $4.29M | $43.16M | $4.75M | $-14.81M | $16.00K | 9.95% | 11.00% | -925.56× | Reported |
| 2021-06-30 | $4.16M | $38.28M | $4.63M | $-15.21M | $38.00K | 10.88% | 12.09% | -400.32× | Reported |
| 2021-03-31 | $4.05M | $31.35M | $4.36M | $-17.34M | $44.00K | 12.93% | 13.89% | -394.00× | Reported |
| 2020-12-31 | $3.92M | $27.71M | $4.21M | $-20.08M | $46.00K | 14.15% | 15.19% | -436.59× | Reported |
| 2020-09-30 | $4.10M | $24.63M | $4.20M | $-23.99M | $47.00K | 16.64% | 17.04% | -510.45× | Reported |
| 2020-06-30 | $4.07M | $25.25M | $3.68M | $-24.38M | $22.00K | 16.11% | 14.56% | -1108.00× | Reported |
| 2020-03-31 | $3.98M | $27.60M | $3.44M | $-22.63M | $14.00K | 14.42% | 12.44% | -1616.50× | Reported |
| 2019-12-31 | $3.73M | $28.23M | $3.58M | $-20.87M | $8.00K | 13.21% | 12.68% | -2608.63× | Reported |
| 2019-09-30 | $3.21M | $25.70M | $2.88M | $-20.09M | $2.00K | 12.50% | 11.21% | -10043.00× | Reported |
| 2019-06-30 | $2.89M | $21.99M | $2.49M | $-17.61M | $32.00K | 13.14% | 11.33% | -550.47× | Reported |
| 2019-03-31 | $2.77M | $19.11M | $2.01M | $-16.08M | $70.00K | 14.47% | 10.53% | -229.76× | Reported |
| 2018-12-31 | $2.47M | $16.69M | $1.52M | $-13.60M | $104.00K | 14.80% | 9.14% | -130.77× | Reported |
| 2018-09-30 | $2.75M | $43.07M | $1.58M | $-3.07M | (m) | 6.37% | 3.66% | (m) | (m) |
| 2018-06-30 | $2.43M | $42.09M | $1.28M | $-3.35M | (m) | 5.77% | 3.04% | (m) | (m) |
| 2018-03-31 | $2.31M | $40.41M | $1.08M | $-4.39M | (m) | 5.71% | 2.68% | (m) | (m) |
| 2017-12-31 | $2.46M | $38.88M | $871.00K | $-5.26M | (m) | 6.31% | 2.24% | (m) | (m) |
| 2017-09-30 | $2.69M | $37.03M | $808.00K | $-5.22M | (m) | 7.27% | 2.18% | (m) | (m) |
| 2017-06-30 | $2.76M | $37.74M | $790.00K | $-4.33M | (m) | 7.32% | 2.09% | (m) | (m) |
| 2017-03-31 | $2.66M | $37.24M | $792.00K | $-3.54M | (m) | 7.14% | 2.13% | (m) | (m) |
| 2016-12-31 | $2.62M | $36.63M | $809.00K | $-3.79M | (m) | 7.15% | 2.21% | (m) | (m) |
| 2016-09-30 | $2.57M | $35.43M | $728.00K | $-4.10M | (m) | 7.25% | 2.05% | (m) | (m) |
| 2016-06-30 | $2.47M | $33.19M | $693.00K | $-5.67M | (m) | 7.44% | 2.09% | (m) | (m) |
| 2016-03-31 | $2.38M | $31.17M | $633.00K | $-6.71M | (m) | 7.64% | 2.03% | (m) | (m) |
| 2015-12-31 | $2.16M | $29.52M | $575.00K | $-6.99M | (m) | 7.32% | 1.95% | (m) | (m) |
| 2015-09-30 | $1.93M | $28.69M | $490.00K | $-7.43M | (m) | 6.73% | 1.71% | (m) | (m) |
| 2015-06-30 | $1.72M | $27.66M | $479.00K | $-7.98M | (m) | 6.20% | 1.73% | (m) | (m) |
| 2015-03-31 | $1.53M | $27.33M | $424.00K | $-8.18M | (m) | 5.60% | 1.55% | (m) | (m) |
| 2014-12-31 | $1.42M | $27.68M | $388.00K | $-5.85M | (m) | 5.12% | 1.40% | (m) | (m) |
| 2014-09-30 | $1.34M | $26.34M | $436.00K | $-4.93M | (m) | 5.09% | 1.66% | (m) | (m) |
| 2014-06-30 | $1.26M | $25.35M | $363.00K | $-3.04M | (m) | 4.99% | 1.43% | (m) | (m) |
| 2014-03-31 | $1.26M | $24.45M | $538.00K | $-2.94M | (m) | 5.15% | 2.20% | (m) | (m) |
| 2013-12-31 | $1.26M | $23.66M | $506.00K | $-3.67M | (m) | 5.33% | 2.14% | (m) | (m) |
| 2013-09-30 | $1.30M | $24.36M | $400.00K | $-2.66M | (m) | 5.33% | 1.64% | (m) | (m) |
| 2013-06-30 | $1.33M | $25.24M | $391.00K | $-1.91M | (m) | 5.27% | 1.55% | (m) | (m) |
| 2013-03-31 | $1.36M | $26.63M | $179.00K | $-15.00K | (m) | 5.12% | 0.67% | (m) | (m) |
| 2012-12-31 | $1.33M | $27.67M | $161.00K | $1.05M | (m) | 4.80% | 0.58% | (m) | (m) |
| 2012-09-30 | $1.24M | $27.00M | $136.00K | $-483.00K | (m) | 4.60% | 0.50% | (m) | (m) |
| 2012-06-30 | $1.21M | $26.59M | $129.00K | $-517.00K | (m) | 4.55% | 0.49% | (m) | (m) |
| 2012-03-31 | $1.15M | $25.99M | $123.00K | $-207.00K | (m) | 4.42% | 0.47% | (m) | (m) |
| 2011-12-31 | $1.20M | $25.41M | $132.00K | $-18.00K | (m) | 4.71% | 0.52% | (m) | (m) |
| 2011-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-12-31 | $1.85M | $24.23M | $163.00K | $-2.75M | (m) | 7.65% | 0.67% | (m) | (m) |
| 2010-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-12-31 | $2.08M | $26.95M | $136.00K | $715.00K | (m) | 7.73% | 0.50% | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Microbot Medical Inc. (MBOT) | $0.089B | -7.97 | |
| KORU Medical Systems, Inc. (KRMD) | United States | $0.151B | -106.78 |
| LENSAR, Inc. (LNSR) | United States | $0.087B | 2.02 |
| SkinHealth Systems Inc. (SKIN) | United States | $0.086B | -3.17 |
| Pulmonx Corp (LUNG) | United States | $0.082B | -1.16 |
| RenovoRx, Inc. (RNXT) | United States | $0.076B | -3.62 |
| FRACTYL HEALTH, INC. (GUTS) | United States | $0.075B | -1.18 |
| Lucid Diagnostics Inc. (LUCD) | United States | $0.170B | |
| CVRx, Inc. (CVRX) | United States | $0.067B | -2.62 |
| DarioHealth Corp. (DRIO) | $0.066B | -1.39 |